Organovo Highlights Phase 2 Results For FXR314 In MASH At The Liver Meeting, Showing Significant Liver Fat Reduction And Improved Safety Profile Compared To Other FXR Agonists
Organovo Highlights Phase 2 Results For FXR314 In MASH At The Liver Meeting, Showing Significant Liver Fat Reduction And Improved Safety Profile Compared To Other FXR Agonists
Organovo在肝脏会议上重点介绍了FXR314在MASH中的2期结果,显示相比其他FXR激动剂,具有显著的肝脂减少和改善的安全性概况。
Organovo Highlights Phase 2 Results For FXR314 In MASH At The Liver Meeting, Showing Significant Liver Fat Reduction And Improved Safety Profile Compared To Other FXR Agonists
Organovo在肝脏大会上重点介绍了FXR314在MASH的2期结果,显示与其他FXR激动剂相比,具有显著的降低肝脂和改善安全性的优势